Quarterly report
Open the filing on sec.gov
TherapeuticsMD, Inc. (TXMD)
Nasdaq: TXMD · Pharmaceutical Preparations · Boca Raton, FL · filing with the SEC since 1995
The companyfiscal 2025, as filed
Revenue$3.0M+71.6%
Net income-$569,000+73.9%
Earnings per share$-0.05+73.7%
Operating cash flow$2.5M+109.7%
Cash$7.5M+47.9%
Debtn/a
Shareholders’ equity$26.9M-1.8%
Shares, diluted11.6M+0.3%
Return on equity-2.1%
The recordfrom its filings
Filings in 202611
Newest filingAug 11 · 10-Q
Annual reportMar 30, 2026
Quarterly reportAug 11, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted0
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Revenue $3.3MNet income -$217,000Cash from operations $3.1Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Annual report, amended
Open the filing on sec.gov
Late annual report notice
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Annual report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.